Short answer
Dianthus Therapeutics, Inc. /DE/ (DNTH) filed its fiscal 2025 10-K annual report with the SEC on Mar 9, 2026. It reported revenue of $2M (−67.3% year over year) and net income of −$162M.
- Top risk flagged: Regulatory risk: Dependence on FDA approval for claseprubart and DNTH212 with uncertain timing and outcomes for clinical trial phases and marketing approvals
FY2025 key financial metrics · XBRL
- Revenue
- $2M
- −67.3% YoY
- Net income
- −$162M
- −91.1% YoY
- Operating margin
- -8739.3%
- −7105.6 pp YoY
- EPS (diluted)
- −$4.20
- −64.7% YoY
- ROE
- -32.9%
- −8.8 pp YoY
- Operating cash flow
- −$129M
- −65.1% YoY
Source: XBRL data from the Dianthus Therapeutics, Inc. /DE/ (DNTH) FY2025 10-K on SEC EDGAR. USD.
Dianthus Therapeutics, Inc. /DE/ FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: Development of claseprubart and DNTH212 biopharmaceutical candidates reliant on outsourced manufacturing and clinical trial services
- New emphasis: Impact of the BIOSECURE Act (Dec 2025) restricting collaborations with certain Chinese biotech firms, including sole manufacturer WuXi Biologics
- Strategic risk shift: Heightened regulatory and geopolitical exposure due to reliance on Chinese contract manufacturers amid increasing U.S.-China trade tensions
- Notable metric: Sole supplier WuXi Biologics in China for claseprubart, with significant supply chain and regulatory risks highlighted in detail
- Unusual fact: First-year reporting impact of U.S. BIOSECURE Act posing potential federal contract and funding prohibitions involving designated Chinese "biotechnology companies of concern"
Management Discussion & Analysis
- Net loss reported; specific profitability or margin figures not provided
- No segment performance data detailed
- Cash flow usage: capital expenditures and operating expenses incurred, no buybacks or dividends mentioned
- Forward-looking: general caution on risks and uncertainties, no specific guidance or outlook disclosed
Risk Factors
- Regulatory risk: Dependence on FDA approval for claseprubart and DNTH212 with uncertain timing and outcomes for clinical trial phases and marketing approvals
- Geopolitical risk: License and development agreements with Tenacia Biotechnology for Greater China involving clinical trial cost sharing and milestone payments up to $15 million
- Operational risk: Reliance on third-party CROs and CDMOs for clinical trials and manufacturing with no owned laboratory or manufacturing facilities
- Competitive risk: Significant R&D spending $145.6M in 2025 to advance claseprubart and DNTH212 amid competition from other biopharma firms in autoimmune neurology space
- Financial risk: Net loss $162.3M in 2025 with cash runway into 2028; future capital needs may dilute shareholders via ATM $200M equity offering capacity
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.